Natixis Investment Managers International Biomarin Pharmaceutical Inc Transaction History

Natixis Investment Managers International

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $1.64 Million - $1.99 Million	22,924 Added 905.37%	25,456 $2.11 Million
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $188,076 - $234,691	2,532 New	2,532 $195,000
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $369,044 - $488,452	-4,605 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $45,457 - $51,168	484 Added 11.74%	4,605 $447,000
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $313,237 - $408,102	4,121 New	4,121 $388,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

Stay updated on Natixis Investment Managers International with notifications on news.